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Objectives. This survey sought to determine actual practices in
the management of acute myocardial infarction on a nationwide
scale.
Background. Few data are available regarding the adoption of
clinical trial results of treatment of myocardial infarction into
“real-world” clinical practice.
Methods. Of 501 intensive care units in France, 373 (74%)
collected data from all patients with myocardial infarction admit-
ted within 48 h of symptom onset during November 1995.
Results. Data from 2,563 patients (71% men; mean age [6SD]
67 6 14 years) were included. Time from symptom onset to
admission was <6 h in 1,467 patients (62%). Thrombolysis was
used in 822 patients (32%) and primary angioplasty in 330 (13%).
The use of reperfusion therapy decreased markedly with age.
During the first 5 days, heparin was prescribed in 96% of patients,
aspirin in 89%, nitrates in 87%, beta-adrenergic blocking agents
in 64%, angiotensin-converting enzyme inhibitors in 46% and
calcium antagonists in 17%. Coronary angiography was per-
formed in 33% of patients, and 58% had echocardiographic
assessment of left ventricular ejection fraction (LVEF). Median
LVEF was 50%. The 5-day mortality rate was 7.7% compared with
12.1% in a previous French survey carried out in 1984. By
multivariate analysis, independent predictors of mortality were
age, anterior infarction, history of stroke and heart failure and,
when added to the model, Killip class and LVEF.
Conclusions. This survey shows that the results of therapeutic
trials have largely translated to clinical practice, resulting in
improved early outcome compared with the early 1980s. However,
continuous efforts should be made to shorten the time delay before
hospital admission and to increase the proportion of elderly
patients receiving reperfusion therapy.
(J Am Coll Cardiol 1997;30:1598–605)
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Acute myocardial infarction still represents a major cause of
morbidity and mortality in industrialized countries (1–5). Over
the past 15 years, there has been considerable progress in the
understanding of its pathophysiologic mechanisms, as well as
in its treatment at the acute stage. The major role of coronary
thrombosis has been clearly established (6), and several pro-
spective, randomized trials have conclusively shown the bene-
fits of the early administration of antithrombotic medications
(7,8). More recent evidence also suggests that primary angio-
plasty can at least equal the results of intravenous thrombolysis
(9). In addition, the benefits of early administration of medi-
cations such as beta-adrenergic-blocking agents or angiotensin-
converting enzyme (ACE) inhibitors is well documented (10–
13), whereas it has been shown (14) that other classes of
medications such as calcium antagonists should be avoided.
Large-scale trials have also shown (15,16) substantially lower
in-hospital mortality with the modern management of acute
myocardial infarction. However, whether and to what extent
these new data have actually influenced the everyday thera-
peutic management of patients presenting with acute myocar-
dial infarction, on a nationwide scale remains speculative. The
present prospective, observational study was therefore de-
signed to assess the current practice of in-hospital manage-
ment of acute myocardial infarction in intensive care units in
France in 1995 and to analyze the results achieved in terms of
early mortality.
Methods
Participating centers. The objective of the study was to
obtain exhaustive data over a 1-month period from all institu-
tions in the French health care system (i.e., university hospitals,
public hospitals or private clinics) to which the patients are
admitted. To this end, a list of all intensive care or coronary
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care units admitting patients at the acute stage of myocardial
infarction at the beginning of 1995 was established. All physi-
cians in charge of these units were then asked to participate in
the study. In all, 501 centers were listed: 47 university hospitals,
317 public hospitals and 137 private clinics, 373 of which finally
participated in the study (74%). The participation rate was
94% (n 5 44) for university hospitals, 76% (n 5 242) for public
hospitals and 64% (n 5 87) for private clinics. One physician
responsible for the study was recruited at each center and
completed one form for each patient meeting the inclusion
criteria and admitted to the intensive care unit during the study
recruitment period. Patient care at each center was performed
according to usual practice and independent of the study.
Patient selection. All consecutive patients admitted to the
participating centers from November 1 to November 30, 1995
were included if they met the following criteria: 1) diagnosis of
acute myocardial infarction based on the presence of serum
enzyme elevation higher than twice the upper limit of normal
for creatine kinase, aspartate transaminase or lactic dehydro-
genase, alone or in combination, with a) chest pain lasting for
at least 30 min and not relieved by nitrates, or b) electrocar-
diographic (ECG) changes on at least two contiguous leads
with pathologic Q waves (at least 0.04 s) or persisting ST
segment elevation or depression .0.1 mV, or both; and 2) time
from the start of symptoms to admission to the intensive care
unit ,48 h.
Data collection. Cardiovascular history; risk factors (smok-
ing status, history of hypertension or treated hypertension,
cholesterol level .2.5 g/liter or treated hyperlipidemia, family
history, diabetes mellitus); and clinical course over the first 5
days after admission, including maximal Killip class as well as
the initial diagnostic and therapeutic management, were re-
corded for each patient. Furthermore, left ventricular ejection
fraction (LVEF), when assessed at any time during the first 5
days, was recorded. The value for LVEF that was used for the
present analyses was determined by the following priority
ranking of the method used: 1) left ventricular (LV) contrast
angiography; 2) radionuclide angiography; 3) echocardiogra-
phy using the Simpson method; 4) echocardiography using the
wall motion index of Berning and Steengaard-Hansen (17); 5)
echocardiography with visual estimation of LVEF. For the
present analyses, LVEF was categorized into four groups: 1)
.50%; 2) 36% to 50%; 3) 21% to 35%; 4) #20%.
Statistical analysis. Continuous variables are presented as
mean value 6 SD. Comparisons between groups were made
using unpaired t tests for continuous variables and chi-square
tests for discrete variables. Multivariate stepwise logistic re-
gression analysis was used to assess the independent prognostic
value of baseline variables. Variables with a p value ,0.20 on
univariate analyses were included in the models. Four models
were used: 1) a model including only clinical and ECG
variables at entry; 2) a model including clinical, ECG variables
at entry and initial modality of treatment with primary coro-
nary angioplasty or intravenous thrombolysis; 3) a model
including baseline clinical and ECG variables, modality of
initial treatment and worst Killip class during the first 5 days;
and 4) a model including baseline clinical and ECG variables,
modality of initial treatment, worst Killip class during the first
5 days and LVEF. Models 1 and 2 were used because Killip
class and LVEF could have been determined late during the
clinical course of the patients and were therefore not true
admission data. Model 3 was used because LVEF was not
measured in a substantial number of patients. A p value , 0.05
was considered significant for all tests.
Results
Baseline variables. A total of 2,800 case record forms were
gathered, of which 317 had to be excluded for not meeting the
entry criteria for the study; 49 corresponded to infarctions that
occurred beyond the time limits of the study (i.e., late October
or early December); in 211, the time from onset of symptoms
to hospital admission exceeded 48 h; and 57 did not fulfill the
required diagnostic criteria for acute myocardial infarction.
Therefore, the study included 2,563 patients (mean age 67 6
14 years; 1,827 men, 736 women) whose baseline characteris-
tics are described in Table 1. The participation of centers and
recruitment of patients according to a geographic subdivision
into six administrative regions showed that the contribution of
each region to the study was well balanced and varied from
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ECG 5 electrocardiogram, electrocardiographic
GUSTO-1 5 Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary
Arteries (trial)
LV 5 left ventricle, left ventricular
LVEF 5 left ventricular ejection fraction
MITI 5 Myocardial Infarction Triage and Intervention (trial)
Table 1. Baseline Variables in All Patients Meeting Entry Criteria
Age (yr) 67 6 14
Men 1,827 (71.3)
Women 736 (28.7)
Risk factors
Smoking 782 (30.9)
Diabetes mellitus 440 (17.4)
Hyperlipidemia 910 (36.3)
Hypertension 1,157 (45.6)
Family history 404 (16.1)
Previous history
PVD 269 (10.6)
Angina 1,032 (40.5)
Previous MI 460 (18.0)
CHF 228 (9.0)
Stroke 168 (6.6)
Data presented are mean value 6 SD or number (%) of patients. CHF 5
congestive heart failure; MI 5 myocardial infarction; PVD 5 peripheral vascular
disease.
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12% to 19%, and the proportion of the total patient population
for each region ranged from 14% to 20%.
The exact time to admission could not be determined in 186
patients (7.3%) but was presumed to be ,48 h. When deter-
mined precisely, the median time from symptom onset to
admission was 4 h 10 min and was ,6 h in 1467 patients (62%).
On admission, chest pain was present in 2,148 patients
(84%). The infarct territory was anterior in 775 patients (30%),
inferior in 995 (39%) and lateral in 90 (3.5%), and 703 patients
(27%) had a non-Q wave myocardial infarction or an infarct of
undetermined location (left bundle branch block, pacemaker).
The prevalence of a non-Q wave myocardial infarction was
higher in patients .75 years old than in younger patients (31%
vs. 26%, p , 0.01).
In-hospital management. Intravenous thrombolysis was
administered in 822 patients (32%), of whom 123 had rescue
coronary angioplasty within 24 h of hospital admission, and 330
(13%) had primary angioplasty. The use of either thrombolysis
or primary coronary angioplasty was strongly related to length
of time since symptom onset and age. In patients admitted
within 6 h, 909 (62%) had either thrombolysis or coronary
angioplasty compared with 147 (33%) for patients admitted
from 6 to 12 h and 77 (17%) for patients admitted $12 h after
symptom onset. In addition, a reperfusion-oriented strategy
was used much less frequently in the older patients, with ,30%
of patients .75 years old and admitted within 6 h of symptom
onset receiving intravenous thrombolysis or undergoing pri-
mary angioplasty (Table 2).
The medications used during the first 5 days after admission
are represented in Figure 1. Heparin and aspirin were pre-
scribed in 96% and 89% of patients, respectively. Beta-
blockers were used in 64%, ACE inhibitors in 46% and
calcium channel blocking agents in 17%. Use of beta-blockers
and ACE inhibitors was related to LV failure and LVEF
(Table 3). Use of beta-blockers decreased markedly with
increasing severity of left heart failure and lower LVEF.
Conversely, there was increasing usage of ACE inhibitors with
increasing severity of heart failure or LV dysfunction, except
for the most severe forms of LV dysfunction (Killip class IV
and LVEF #20%).
Left heart catheterization was performed in 856 patients
(33%), including those with primary angioplasty, and LVEF
was calculated in 517 of them. Furthermore, 1,480 patients
(58%) had at least one echocardiographic examination, and 26
Table 2. Relation Between Age Category and Use of Reperfusion-Oriented Strategy (intravenous
thrombolysis or primary percutaneous transluminal coronary angioplasty)
Age (yr)
p Value
(chi-square test),50 51–60 61–70 71–75 76–80 .80
All pts (no.) 394 421 621 411 237 479
Lysis or PTCA
No. 253 263 334 166 67 69 , 0.0001
% 64 62.5 54 40 28 14
Pts admitted ,6 h after symptom
onset (no.)
251 268 358 234 128 228
Lysis or PTCA
No. 208 207 254 138 50 52 , 0.0001
% 83 77 71 59 39 23
PTCA 5 percutaneous transluminal coronary angioplasty; pts 5 patients.
Figure 1. Medications used during
first 5 days of hospital admission
after infarction.
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(1%) underwent radionuclide LV angiography. On the whole,
LVEF was determined within 5 days of hospital admission in
1,720 patients (67%). The median value of LVEF was 50%,
with 16% of patients having severely depressed LV function
(LVEF #35%).
During the first 5 days, cardiac surgery was performed in 17
patients (0.7%) and late coronary angioplasty in 29 (1.1%).
Clinical course and 5-day mortality. The complications
observed during the first 5 days of the hospital period included
ventricular arrhythmias in 796 patients (31%), recurrent an-
gina in 533 (21%), conduction disturbances in 390 (15%), left
heart failure in 359 (14%), supraventricular arrhythmias in 299
(12%) and mechanical complications in 106 (4%). The 1- and
5-day mortality rates were 2.2% (57 patients) and 7.7% (197
patients), respectively, and increased markedly with age (Fig.
2) and was double in women compared with men. Among
clinical variables, diabetes mellitus, hypertension and history of
angina, peripheral vascular disease, stroke or congestive heart
failure were significantly related to a poorer in-hospital out-
come, whereas smoking and known hyperlipidemia were re-
lated to an improved 5-day survival (Table 4). In addition,
patients with a Q wave or anterior wall infarction or those in
Killip class II or higher had a poorer prognosis. Patients
receiving intravenous thrombolysis had a significantly im-
proved outcome, and a trend for improved survival was also
observed for patients undergoing primary angioplasty. Multi-
variate analyses showed that among admission variables, age,
anterior wall myocardial infarction and history of stroke or
congestive heart failure were independent predictors of sur-
vival; initial treatment modality (primary angioplasty or throm-
bolysis vs. no such treatment) was not an independent predic-
tor of survival (Table 5).
Discussion
Representativeness of study sample. How the results of
controlled studies of different treatment modalities in acute
myocardial infarction translate into actually applied clinical
practice on a large scale remains uncertain. To our knowledge,
the present study is the first to analyze the current manage-
ment of myocardial infarction in intensive care units (including
a survey of both treatment modalities and diagnostic proce-
dures used, with particular emphasis on determination of LV
function) on a nationwide scale, irrespective of the type of
Table 3. Relation Between Usage of Beta-Adrenergic Blocking Agents or Angiotensin-Converting
Enzyme Inhibitors and Killip Class or Left Ventricular Ejection Fraction
Killip Class
p Value
(chi-square test)
I
(n 5 1,683)
II
(n 5 521)
III
(n 5 190)
IV
(n 5 169)
Beta-blockers 1,320 (78%) 249 (48%) 45 (24%) 33 (20%) , 0.0001
ACE inhibitors 698 (42%) 304 (58%) 117 (62%) 50 (30%) , 0.0001
LVEF
.50%
(n 5 823)
36–50%
(n 5 615)
21–35%
(n 5 238)
#20%
(n 5 44)
Beta-blockers 645 (78%) 429 (70%) 94 (39%) 11 (25%) , 0.0001
ACE inhibitors 306 (37%) 350 (57%) 151 (63%) 19 (43%) , 0.0001
Data presented are number (%) of patients. ACE 5 angiotensin-converting enzyme; LVEF 5 left ventricular
ejection fraction.
Figure 2. Five-day mortality according to pa-
tient age category.
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admitting institution. The present survey may be considered
highly representative of clinical practice in France by the end
of 1995. Although the participation rate was higher in univer-
sity hospitals, it remained satisfactory (.60%) for general
hospitals and private clinics. In addition, when the recruitment
of patients was analyzed according to a geographic subdivision
into six administrative regions, no imbalance was seen from
one region to another. The representativeness of the study
sample is therefore likely to be adequate. From the results of
the present study, it may be inferred that ;40,000 patients are
admitted to an intensive care unit for recent acute myocardial
infarction in France annually. However, this figure does not
take into account the number of patients who die before
Table 4. Univariate Analysis of Factors Related to Five-Day Mortality
No. of
Pts
Mortality at Day 5
[no. (%) of pts] p Value
Age (yr)
#50 394 7 (1.8%)
51–60 421 12 (2.9%)
61–70 621 27 (4.3%)
71–75 411 33 (8.0%)
76–80 237 26 (11.0%)
.80 479 92 (19.2%) 0.0001
Men 1,827 106 (5.8%)
Women 736 91 (12.4%) 0.0001
Risk factors
Family history
No 2,102 161 (7.7%)
Yes 404 21 (5.2%) 0.0808
Smoking
No 1,746 165 (9.5%)
Yes 782 26 (3.3%) 0.0001
Hypertension
No 1,383 83 (6.0%)
Yes 1,157 110 (9.5%) 0.0009
Diabetes mellitus
No 2,087 147 (7.0%)
Yes 440 45 (10.2%) 0.0220
Hyperlipidemia
No 1,598 142 (8.9%)
Yes 910 49 (5.4%) 0.0014
Previous history
Angina
No 1,515 101 (6.7%)
Yes 1,032 92 (8.9%) 0.0353
MI
No 2,103 152 (7.2%)
Yes 460 45 (9.5%) 0.0624
CHF
No 2,316 157 (6.8%)
Yes 228 36 (15.8%) 0.0001
PVD
No 2,279 161 (7.1%)
Yes 269 31 (11.5%) 0.0088
Stroke
No 2,383 168 (7.0%)
Yes 168 26 (15.5%) 0.0001
Admission data
Q wave MI
No 692 39 (5.6%)
Yes 1,820 151 (8.3%) 0.0242
Anterior wall MI
No 1,788 106 (5.9%)
Yes 775 91 (11.7%) 0.0001
Initial treatment modality
Thrombolysis
No 1,741 151 (8.7%) 0.0063
Yes 822 46 (5.6%)
Primary PTCA
No 2,233 178 (8.0%)
Yes 330 19 (5.8%) 0.1588
Killip class 0.0001
I 1,683 37 (2.2%)
II 521 39 (7.5%)
III 190 28 (14.7%)
IV 169 93 (55.0%)
Abbreviations as in Tables 1 and 2.
Table 5. Multivariate Logistic Regression Analyses of Factors
Related to Five-Day Mortality
RR (95% CI)
Clinical and ECG Model
Age (continuous) 1.07 (1.05–1.08)
Anterior wall MI 2.19 (1.58–3.06)
History of stroke 1.99 (1.22–3.23)
History of CHF 1.64 (1.06–2.56)
Clinical and ECG Model With Age as a Categoric Variable
Age (vs. with age #50 yr)
51–60 yr 1.54 (0.60–3.95)
61–70 yr 1.78 (0.96–3.31)
71–75 yr 3.01 (1.83–4.94)
76–80 yr 3.17 (1.92–5.22)
.80 yr 4.65 (3.33–6.47)
Anterior wall MI 2.12 (1.56–2.89)
History of stroke 1.81 (1.12–2.91)
Clinical, ECG and Treatment Modality Model
Age (continuous) 1.07 (1.05–1.08)
Anterior wall MI 2.19 (1.58–3.06)
History of stroke 1.99 (1.22–3.23)
History of CHF 1.64 (1.06–2.56)
Clinical, ECG and Treatment Modality Model, Including Killip Class
Age (continuous) 1.05 (1.03–1.07)
Anterior wall MI 1.97 (1.35–2.88)
History of stroke 2.03 (1.16–3.54)
Killip class
II 2.05 (1.22–3.43)
III 3.61 (1.98–6.57)
IV 34.94 (9.65–126.48)
Clinical, ECG, Treatment Modality, Killip Class and LVEF Model
Age (continuous) 1.06 (1.04–1.09)
Killip class
II 1.41 (0.67–2.97)
III 2.36 (0.97–5.74)
IV 13.07 (6.26–27.28)
LVEF (%)
36–50 3.20 (1.33–7.70)
21–35 7.01 (2.81–17.50)
#20 14.30 (4.50–45.50)
CI 5 confidence interval; ECG 5 electrocardiographic; RR 5 relative risk;
other abbreviations as in Tables 1 and 3.
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admission to an intensive care unit or those admitted .48 h
after the onset of symptoms.
Time to admission. Our results show that the time delay
before hospital admission is long and has remained virtually
unchanged since the early 1980s: Only 62% of patients are
admitted within 6 h of symptom onset, a rate similar to that
observed in previous reports in France (18–20). This rate,
which is particularly disappointing compared with that re-
ported for other countries, deserves clarification as to the exact
reasons for the delay in admission to hospital, and efforts at
increasing public awareness are warranted. Recently, it has
been shown (21) that a multimedia public campaign could
result in a significant time savings to hospital admission in
patients presenting with myocardial infarction, without an
excess in hospital admissions for noncardiac chest pain.
Therapeutic management. In contrast, considerable changes
have occurred in therapeutic management over the past de-
cade (18,20,22,23). Reperfusion therapy, either by intravenous
thrombolysis or primary angioplasty, is used in .60% of
patients admitted within 3 h of symptom onset and in .50% of
those admitted from 3 to 6 h. In all, 32% of all patients
received intravenous thrombolysis, a figure that seems remark-
ably stable over time since the late 1980s (18–20) and from one
country to another (1,24,25). However, these figures remain
lower than expected because true contraindications to throm-
bolytic therapy are unusual (18). In particular, although the
benefits of thrombolysis in elderly patients have been estab-
lished (26,27), the proportion of elderly subjects presenting
early after symptom onset who received intravenous thrombol-
ysis remained abnormally low. This trend to an abnormally low
usage of thrombolysis in elderly patients has also been re-
ported in several other countries (28,29).
Conversely, the results of randomized trials of adjunctive
medical treatment in acute myocardial infarction seem to have
been largely translated into clinical practice. Compared with
two, more limited, previous French multicenter surveys, car-
ried out in 1988 (22) and 1991 (23), prescription of aspirin has
increased from 63% to 79% and 89% in the present study, that
of beta-blockers from 41% to 67% and 64%, that of ACE
inhibitors from nil to 9% and 46% at present, whereas that of
calcium antagonists has decreased from 62% to 35% and 17%
in the present survey. Similar trends had also been noted in the
French Monitoring Trends and Determinants in Cardiovascu-
lar Disease (MONICA) centers (20) when medical prescrip-
tions in 1985 and 1991 were compared. Compared with the
figures reported from other countries in the early 1990s, the
prescription of beta-blockers seems equivalent (25,30,31) or
higher (29,32) and that of calcium antagonists lower (25,30,32).
In a recently published survey of the prescription of beta-
blockers by cardiologists in patients with a myocardial infarc-
tion in the United States in 1992, Brand et al. (33) report a
48% level of prescription in patients with no contraindications
for beta-blocker use, stressing the insufficient level of compli-
ance of cardiologists with their speciality’s guidelines. In this
regard, our results appear more encouraging and parallel those
reported in Great Britain in a study (34) assessing the evolu-
tion of prescriptions from 1987 to 1989. The use of ACE
inhibitors has almost doubled that observed in the early 1990s
(25,30–32), which is evidence of the impact of recent trial
results on ACE inhibitor use at the acute stage of infarction
(10–13). In addition, the correlation that we found between
prescription of ACE inhibitors and LV function shows that
these medications were adequately prescribed. Prescription of
aspirin has seldom been analyzed. In the Gruppo Italiano per
lo Studio della Streptochiasi nell’Infarto Miocardico (GISSI)
centers, Venturini et al. (28) found that only 64% of patients
admitted for acute myocardial infarction received aspirin
during the first hospital day. Whether prescription of these
medications at the acute stage is followed by continued admin-
istration for secondary prevention at the chronic stage is
uncertain, but it has been previously observed (35) that there
was a comparative stability in drug prescription over the 5
years after an episode of myocardial infarction.
In-hospital outcome and early mortality. Our study was
not designed to assess the therapeutic efficacy of any one
medical or interventional treatment; however, it is striking to
observe that the aforementioned changes in therapeutic man-
agement were accompanied by a marked reduction of early
mortality compared with previous data collected in France. A
previous multicenter French survey (18) carried out in 1984
showed a 5-day mortality rate of 12.1% in patients admitted to
intensive care units and whose age was similar to patients in
the present study. The present rate of 7.7% therefore repre-
sents a 36% decrease in early mortality over the past 11 years.
Similar results were found in several other longitudinal studies
in selected centers in France (36,37). A continued decline in
early mortality in patients admitted with an acute myocardial
infarction has also been reported in many other countries
(1,25,29,34,38–40). The mortality rate in our study is compa-
rable to that observed in the Global Utilization of Streptoki-
nase and Tissue Plasminogen Activator for Occluded Coronary
Arteries (GUSTO-1) trial (16) and is also similar to that found
in the community-wide Myocardial Infarction Triage and
Intervention (MITI) survey in the United States (41). How-
ever, the results of the present pertain only to patients
admitted to the hospital, not to those dying before hospital
admission.
By univariate analysis, numerous factors were related to
early mortality. However, after multivariate adjustment, only
age, anterior wall infarction, history of congestive heart failure,
previous history of stroke and Killip class were found to be
independent correlates of mortality. LVEF, as measured in
everyday practice, was also a major independent predictor of
early mortality, although the statistical power of this factor was
most likely reduced because it was frequently missing in
patients who died very early. Age is a well known prognostic
factor in patients admitted with an acute myocardial infarction.
Killip class, LVEF and, to a lesser degree, anterior location of
the infarct reflect the extent of myocardial damage and remain
major indicators of early outcome. History of stroke is not
usually analyzed in studies of prognostic indicators at the acute
stage of infarction: Its independent prognostic significance
stresses the prognostic importance of concomitant morbidity.
Interestingly, age, Killip class and anterior infarction were also
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three of the most potent predictors of mortality in patients with
thrombolysis in the GUSTO-1 study (42), showing that similar
predictive factors can be found in patients treated with intra-
venous thrombolysis and in unselected populations with myo-
cardial infarction. Finally, reperfusion therapy by intravenous
thrombolysis or primary angioplasty was related to early mor-
tality by univariate but not by multivariate analysis. This
finding, similar to that observed in the MITI study (41), can
possibly be explained by the confounding influence of early left
ventricular dysfunction. More important, the time point for
assessing mortality in the present study may have been too
early to evaluate the full impact of reperfusion therapy because
it has been shown (43) that fibrinolytic therapy was associated
with an increase in mortality in the first 2 days after adminis-
tration that was counterbalanced by its favorable effects in the
subsequent month.
Conclusions. The present nationwide study of patients
admitted with an acute myocardial infarction in France con-
firms that the results of prospective trials, including recent data
from ACE inhibitor trials, have been largely adopted into
clinical practice (44). The resulting improvement in patient
management has been accompanied by a marked decrease in
early mortality. However, continuing efforts should be made to
shorten the time delay before hospital admission, possibly by
improving public awareness. In addition, to increase the pro-
portion of elderly patients receiving reperfusion therapy, treat-
ing physicians should be made aware of the favourable benefit/
risk ratio of thrombolysis in this specific category of patients.
We are indebted to all physicians in the participating centers without whose
collaboration this study would not have been possible and to Philippe Amouyel,
MD for technical help.
Appendix
Participating Centers*
Alsace: Colmar (2), Haguenau, Mulhouse (3), Schiltigheim, Strasbourg (2),
Wissenbourg. Aquitaine: Agen (2), Aire sur l’Adour, Arcachon, Bayonne (2),
Bergerac, Biarritz, Bizanos, Bordeaux (2), Dax, Lesparre Me´doc, Libourne,
Marmande, Me´rignac, Mont de Marsan, Orthez, Pau, Pe´rigueux, Pessac, Sarlat.
Auvergne: Aurillac, Clermont-Ferrand, Issoire, Mauriac, Montluc¸on (2), Mou-
lins, Saint-Flour, Vichy. Basse-Normandie: Alenc¸on, Argentan, Avranches,
Bayeux, Caen, Cherbourg, Coutances, Flers, Granville, Lisieux, Saint-Lo, Trou-
ville, Vire. Bourgogne: Autun, Auxerre, Beaune, Chalon sur Saoˆne, Dijon, Le
Creusot, Macon, Nevers, Paray le Monial, Semur en Auxois, Tonnerre, Fontaine
les Dijon, Montceau les Mines. Bretagne: Brest (2), Dinan, Douarnenez,
Fouge`res, Paimpol, Pont l’Abbe´, Rennes (2), Saint Brieuc, Vannes. Centre:
Blois, Bourges, Chambray les Tours, Chateauroux, Chinon, Dreux, Gasville
Oiseme, Le Coudray, Nogent le Rotrou, Orle´ans (2), Saint Amand Montrond,
Tours, Vendoˆme. Champagne: Chalons sur Marne, Chareleville Mezie`res,
Chaumont, Epernay, Langres, Reims (2), Romilly sur Seine, Sedan, Saint Dizier,
Troyes, Vitry le Franc¸ois. Corse: Ajaccio (2), Bastia. Franche-Comte´: Belfort,
Besanc¸on (2), Lons le Saunier, Monbe´liard, Pont d’Hery, Vesoul. Haute-
Normandie: Bernay, Dieppe, Elbeuf, Evreux (2), Fecamp, Harfleur, Le Havre,
Petit Quevilly, Pont-Audemer, Rouen (2), Vernon. Ile de France: Antony,
Argenteuil, Aubervilliers, Aulnay sous Bois, Bagnolet, Bobigny, Boulogne-
Billancourt, Briis sous Forge, Bry sur Marne, Champigny sur Marne, Clamart,
Clichy, Corbeil Essonnes, Coulommiers, Cre´teil, Dourdan, Drancy, Evry, Fon-
tainebleau, Garches, Gonesse, Issy les Moulineaux, Le Chesnay (2), Le Raincy,
Mantes la Jolie, Meaux, Melun, Meulan, Montfermeil, Montmorency, Mon-
treuil, Nanterre, Paris (13), Poissy, Pontoise, Port- Marly, Provins, Rambouillet,
Rueil-Malmaison, Se`vres, Saint-Cloud, Saint-Denis (2), Saint-Mande´, Saint
Maur des Fosse´s, Suresnes, Yerres. Languedoc-Roussillon: Ale`s, Bagnols sur
Ce`ze, Be´ziers, Carcassonne, Montpellier (2), Narbonne (2), Nıˆmes (2), Perpig-
nan (2), Se`te. Limousin: Gue´ret, Limoges (3), Saint-Junien, Sainte Feyre, Saint
Yrieix, Tulle, Ussel. Lorraine: Bar le Duc, Briey, Epinal (2), Essey les Nancy,
Forbach, Freyming Merlebach, Metz, Nancy (2), Neufchateau, Remiremont,
Saint Die (2), Thionville, Vandoeuvre le`s Nancy, Verdun, Vittel. Midi-Pyre´ne´es:
Albi (2), Auch, Cahors, Castres (2), Cornebarrieu, Mazamet, Millau, Montauban
(2), Muret, Saint Gaudens, Saint-Jean, Tarbes (2), Toulouse (4). Nord: Arras,
Avesnes sur Helpe, Bethune, Bois Bernard, Boulogne sur Mer, Cambrai (2),
Dechy, Dunkerque (2), Le Quesnoy, Lens, Lille (2), Lomme, Rang du Fliers,
Roubaix, Tourcoing, Valenciennes, Wattrelos, Saint Pol sur Ternoise. Pays de
Loire: Angers (2), Challans, Cholet, La Roche sur Yon, Laval, Le Mans (2), Les
Sables d’Olonne, Nantes, Saumur, Saint Herblain, Saint Nazaire. Picardie:
Abbeville, Amiens (3), Beauvais, Chauny, Creil (2), Hirson, Laon, Saint Quentin.
Poitou-Charentes: Bressuire, Chatellererault (2), Cognac, Jonzac, La Rochelle,
Niort (2), Poitiers, Rochefort, Royan, Saint Jean d’Ange´ly, Saint Michel,
Thouars. Provence-Coˆte d’Azur: Aix en Provence, Antibes, Arles, Aubagne (2),
Avignon, Brianc¸on, Cannes (2), Carpentras, Draguignan, Digne, Fre´jus, Gap,
Grasse, Hye`res, Manosque, Marignane, Marseille (10), Martigues, Monace,
Nice, Orange, Salon de Provence, Saint Laurent du Var, Toulon (2). Rhoˆne-
Alpes: Albertville, Annecy, Annonay, Belley, Bourg en Bresse, Bourgoin Jallieu,
Chambe´ry, Feurs, Firminy, Givors, Grenoble (2), Lyon (4), Montbrison, Mon-
te´limar, Privas, Roanne, Romans sur Ise`re, Sallanches, Saint Chamond, Saint
Etienne, Saint Jean de Maurienne, Saint Martin d’Heres, Saint Vallier, Thonon
les Bains, Valence, Vienne, Villefranche, Voiron.
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